Intraocular drug delivery platform
An intraocular drug delivery platform including a ring having an anterior surface and a posterior surface opposite the anterior surface, a central aperture formed by the ring, a first haptic coupled to and extending outwards from the ring, a second haptic coupled to and extending outwards from the ring, a first drug eluting mass operably coupled to the anterior surface of the ring, and a second drug eluting mass operably coupled to the anterior surface of the ring and positioned directly opposite of the first drug eluting mass.
1. An intraocular implant comprising:
an intraocular drug delivery platform comprising:
at least a partial ring comprising an anterior surface, a posterior surface opposite the anterior surface, and a central aperture formed by the ring;
at least one discrete compartment comprising a first discrete compartment extending anteriorly from the anterior surface of the ring and integrated with the ring;
a first drug eluting mass comprising a therapeutic agent positioned in the first discrete compartment;
a retention structure extending posteriorly from the posterior surface of the at least a partial ring and at least partially circumscribing the central aperture; and
an intraocular lens (IOL) configured to be retained in position by the retention structure of the intraocular drug delivery platform, the IOL comprising an optic, a first lens haptic, and a second lens haptic.
2. The intraocular implant of claim 1 , wherein the first drug eluting mass is in the form of a slab.
3. The intraocular implant of claim 1 , wherein the retention structure comprises a skirt.
4. The intraocular implant of claim 1 , wherein the first drug eluting mass includes a membrane to control a rate of elution of the therapeutic agent.
5. The intraocular implant of claim 4 , wherein the membrane is a semi-permeable membrane.
6. The intraocular implant of claim 1 , wherein the therapeutic agent of the first drug eluting mass is dispersed within a first matrix of the first drug eluting mass.
7. The intraocular implant of claim 6 , wherein the first matrix is a silicone matrix.
8. The intraocular implant of claim 1 , wherein the therapeutic agent comprises bimatoprost.
9. The intraocular implant of claim 8 , wherein the bimatoprost is in a crystalline form.
10. The intraocular implant of claim 1 , wherein the at least one discrete compartment further comprises a second compartment, and a second drug eluting mass being positionable in the second compartment.
11. The intraocular implant of claim 10 , wherein the second compartment extends anteriorly from the anterior surface of the ring.